Literature DB >> 8617482

Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia.

T Naka1, T Fukuda, H Chuman, Y Iwamoto, Y Sugioka, M Fukui, M Tsuneyoshi.   

Abstract

Chordoma shows various degrees of atypia histologically, however, the relationship between the histological features and the biological behavior still remains controversial. The authors subclassified 17 specimens with chordoma into two groups (ie, trabecular type showing a trabecular patterns and solid type mainly consisting of a diffuse proliferation of tumor cells). The histological grading was performed according to the degree of nuclear atypia on a scale of 1 to 3. Using DNA flow cytometric and immunohistochemical techniques, both the proliferative index (% S + G2 + M phase) and the MIB-1 labeling index (LI) of the tumor cells were estimated regarding their proliferative activities. In addition, p53 overexpression was also investigated using immunohistochemical techniques. There were eight (47.1%) specimens of trabecular type and nine (52.9%) of solid type. In nine specimens of solid type, those with higher nuclear atypia (grade 2 or 3) were significantly more frequent (five specimens, 55.6%) than in trabecular type in which all of the eight specimens were grade 1 (P = 0.44). The proliferative index was significantly higher in grade 2 or 3 lesions than in grade 1 lesions (P = .014), and the MIB-1 LI tended to be higher in solid type than in trabecular (P = .088). p53 overexpression was detected in two specimens of solid type, and the MIB-1 LI in these two specimens was significantly higher (P = .037) than that in the specimens without p53 overexpression. It was considered that the preceding anaplastic histological features, including either diffuse proliferation or high grade nuclear atypia, together with p53 overexpression, were thus closely related to the proliferative activities in chordomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617482     DOI: 10.1016/s0046-8177(96)90112-4

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

3.  Immunohistochemical analysis of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM) in chordoma.

Authors:  T Naka; Y Oda; Y Iwamoto; N Shinohara; H Chuman; M Fukui; M Tsuneyoshi
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Metastatic chordoma detected by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Conor Fearon; Aurelie Fabre; Eric J Heffernan; Stephen J Skehan; Niall Swan; Michael P Keane; Marcus W Butler
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

Review 5.  Clival Chordoma: Case Report and Review of Recent Developments in Surgical and Adjuvant Treatments.

Authors:  Ayaz M Khawaja; Anand Venkatraman; Maira Mirza
Journal:  Pol J Radiol       Date:  2017-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.